Fast Five Quiz: Myelodysplastic Syndrome Management

Emmanuel C. Besa, MD


May 12, 2021

Figure 1. Illustration of chromosomal deletion.

Deletion 7q confers a poor prognosis and would add two points to the IPSS-R score. The IPSS-R, a revision to IPSS, is considered the standard risk assessment in MDS.

In measuring response to AML-like therapy, the most important prognostic factors are karyotype and presence of TP53 mutations. Patients with unfavorable karyotype (−7/del7q or complex karyotype) or TP53 mutations have low CR rates and short durations of response.

Deletion 5q and deletion 20q each confer a good prognosis and add one point to the IPSS-R score. Deletion 11q confers a very good prognosis and adds no points to the IPSS-R score.

Learn more about the IPSS-R.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: